The objective of Co-ACT is to protect and stimulate the R&D activities, production and export activities in order to consolidate Belgium’s status as an investment location for ATMPs companies.

Its members include  Bone Therapeutics, Celyad, Novadip Biosciences, Promethera Biosciences, and TiGenix.

 

Sign up to the newsletter